Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Payables (2016 - 2025)

Historic Payables for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to $1.7 million.

  • Marker Therapeutics' Payables fell 3490.7% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 3490.7%. This contributed to the annual value of $1.8 million for FY2024, which is 50.2% up from last year.
  • Per Marker Therapeutics' latest filing, its Payables stood at $1.7 million for Q3 2025, which was down 3490.7% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Marker Therapeutics' Payables ranged from a high of $11.1 million in Q4 2021 and a low of $1.7 million during Q3 2025
  • For the 5-year period, Marker Therapeutics' Payables averaged around $3.8 million, with its median value being $2.6 million (2024).
  • The largest annual percentage gain for Marker Therapeutics' Payables in the last 5 years was 10001.31% (2022), contrasted with its biggest fall of 7735.78% (2022).
  • Over the past 5 years, Marker Therapeutics' Payables (Quarter) stood at $11.1 million in 2021, then crashed by 77.36% to $2.5 million in 2022, then tumbled by 30.78% to $1.7 million in 2023, then increased by 0.5% to $1.8 million in 2024, then fell by 5.09% to $1.7 million in 2025.
  • Its Payables stands at $1.7 million for Q3 2025, versus $2.3 million for Q2 2025 and $2.1 million for Q1 2025.